Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'R2' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'R2' found in 1 term [] and 26 definitions []
previous     6 - 10 (of 27)     next
Result Pages : [1]  [2 3 4 5 6]
Searchterm 'R2' was also found in the following services: 
spacer
News  (2)  Resources  (1)  Forum  (3)  
 
Clariscan™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and will be developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours.
At this time the development of Clariscan™ is discontinued.

See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide.
Drug Information and Specification
NAME OF COMPOUND
Feruglose, PEG-feron, USPIO, NC100150
DEVELOPER
CENTRAL MOIETY
Fe
CONTRAST EFFECT
T2, Predominantly negative enhancement
R1=20, R2=35, B0=0.5T
PHARMACOKINETIC
Intravascular
CONCENTRATION
29.8 mg Fe/mL
PREPARATION
Suspend in an isotonic glucose solution
INDICATION
Cardiovascular
DEVELOPMENT STAGE
?
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
spacer
 
Further Reading:
  News & More:
GE Healthcare expands MRI contrast media product range in Europe with launch of macrocyclic agent ClariscanTM
Wednesday, 1 March 2017   by www.businesswire.com    
GE Healthcare announces FDA approval of macrocyclic MRI contrast agent Clariscan
Monday, 4 November 2019   by www.itnonline.com    
MRI Resources 
Bioinformatics - Pathology - MR Guided Interventions - - Brain MRI - Health
 
Dotarem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Dotarem® is a paramagnetic ionic MRI contrast agent. Extracellular contrast agents like Dotarem®, can be bolus injected because of the relatively low rate of side effects. This contrast medium is useable to enhance signal intensity in magnetic resonance imaging for intracranial and spinal lesions with an abnormal blood brain barrier or abnormal vascularity, and in whole body imaging.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
DEVELOPER
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
1350 mosm/kgH2O
CONCENTRATION
0.5 mol/L
DOSAGE
0.1 mmol/kg / 0.2mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15, 20mL
Pre-filled syringes of 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
France, Switzerland
Artirem®
for sale
Australia
for sale
spacer

• View the DATABASE results for 'Dotarem®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
  News & More:
RSNA Statement on Gadolinium-Based MR Contrast Agents
Thursday, 1 February 2018   by www.rsna.org    
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
MRI Resources 
Safety Products - Spine MRI - Safety Training - Examinations - IR - Spectroscopy pool
 
DyamideInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Some dyamides are under preclinical development as intravascular MRI contrast agents for blood flow perfusion.

Short name: Dy-DTPA-BMA, generic name: Sprodyamide, central moiety: Dy2+, contrast effect: T2*enhanced, relaxivity: r1=3.4, r2=3.8, B0=0.47,

Short name: Dy-DTPA, central moiety: Dy2+, contrast effect: T2*enhanced,

Short name: Albumin-(Dy-DTPA)x, central moiety: Dy2+, contrast effect: T2*enhanced.
spacer
 
Further Reading:
  Basics:
Dysprosium
   by www.scescape.net    
Searchterm 'R2' was also found in the following services: 
spacer
News  (2)  Resources  (1)  Forum  (3)  
 
Endorem™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
A brand name for ferumoxide (same as Feridex®)
Endoremâ„¢ is a black to reddish-brown aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Endoremâ„¢ is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased.

See also Ferumoxide.
Drug Information and Specification
NAME OF COMPOUND
Dextran-coated ferumoxide, Ami-25
CENTRAL MOIETY
Fe2+/Fe3+
CONTRAST EFFECT
T2, predominantly negative enhancement
r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC
RES-directed
340 mosm/kgH2O
CONCENTRATION
11.2mg Fe/ml
DOSAGE
15 µmol Fe/kg
PREPARATION
Suspend in an isotonic glucose solution
INDICATION
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Brazil
Endorem™
for sale
Argentina
for sale
South Korea
for sale
Israel
for sale
spacer

• View the DATABASE results for 'Endorem™' (5).Open this link in a new window

 
Further Reading:
  News & More:
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
MRI Resources 
Health - Quality Advice - Nerve Stimulator - Examinations - Journals - Education pool
 
Feridex°InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
A brand name for ferumoxide (same as Endorem™)
Feridex® is a sterile aqueous colloid of superparamagnetic iron oxide associated with dextran for intravenous administration as a MRI contrast medium for the detection of liver lesions that are associated with an alteration in the RES.
Feridex® is taken up by macrophages, found only in healthy liver cells but not in most tumors. Tissues such as metastases, primary liver cancer, cysts and various benign tumors, adenomas and hyperplasia retain their native signal intensity, so the contrast between normal and abnormal tissue is increased. Feridex® is a black to reddish-brown aqueous colloid.
See also Ferumoxide.

In November 2008, AMAG Pharmaceuticals, Inc. decided to discontinue the manufacturing of Feridex.
Drug Information and Specification
NAME OF COMPOUND
Dextran-coated ferumoxide, Ami-25
CENTRAL MOIETY
Fe2+/Fe3+
CONTRAST EFFECT
T2, predominantly negative enhancement
r1=40.0, r2=160, B0=0.47T
PHARMACOKINETIC
RES-directed
340 mosm/kgH2O
CONCENTRATION
11.2mg Fe/ml
DOSAGE
15 µmol Fe/kg
PREPARATION
Suspend in an isotonic glucose solution
INDICATION
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Ampoule of 8 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
-
-
EU
Brazil
for sale ?
Argentina
for sale ?
South Korea
for sale ?
Israel
for sale ?
spacer

• View the DATABASE results for 'Feridex®' (9).Open this link in a new window

 
Further Reading:
  Basics:
AMAG Pharmaceuticals Inc. Q4 2008 Earnings Call Transcript
Friday, 27 February 2009   by seekingalpha.com    
Feridex Prescribing Information(.pdf)
   by berlex.bayerhealthcare.com    
  News & More:
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
MRI Resources 
Spectroscopy - Cochlear Implant - MRI Reimbursement - Diffusion Weighted Imaging - Knee MRI - Brain MRI
 
previous      6 - 10 (of 27)     next
Result Pages : [1]  [2 3 4 5 6]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



How AI will impact MRI :
only diagnostics 
saving time 
reducing cost 
makes planning obsolete 
reduce human knowledge 
not at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 1 May 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]